PRFX — PRF Technologies Share News
0.000.00%
Last trade - 00:00- $2.25m
- -$5.67m
- $0.02m
Brief: Painreform Announces Receipt Of Nasdaq Minimum Bid Price Notification
PainReform Ltd expected to post a loss of $2.40 a share - Earnings Preview
Brief: PainReform Announces Pricing Of $4 Million Public Offering
Brief: PainReform Reaches 50% Enrollment In Second Part Of Its Phase 3 Clinical Trial Of PRF-110 In Bunionectomy
Brief: PainReform Provides Year-End Business Update
Brief: Painreform To Commence Second Part Of Phase 3 Clinical Trial To Evaluate PRF-110 Following Positive FDA Review of Drug Master File
Brief: PainReform Regains Compliance With Nasdaq Continued Listing Requirements
Brief: Painreform Ltd Says Company's Supplier Of API Has Received A Deficiency Notice From FDA Related To Its Drug Master File
PainReform falls after update on lead drug trial
Brief: Painreform Provides Business Update For The First Quarter Of 2023
Brief: PainReform Announces Positive Safety Data In First Part Of Phase 3 Clinical Trial Of PRF-110 In Patients Undergoing Bunionectomy Surgery
Brief: Painreform Completes First Part Of Phase 3 Clinical Trial In Patients Undergoing Bunionectomy Surgery
U.S. STOCKS ON THE MOVE-Mirum, AMC Entertainment, crypto stocks
U.S. STOCKS ON THE MOVE-Meta, Univar, Alphabet, Uber
Brief: PainReform Announces Phase 3 Clinical Trial Commencement To Evaluate PRF-110
PainReform up on initiating late-stage study of lead drug candidate
U.S. STOCKS ON THE MOVE-Microsoft, Manchester United, Coty
Brief: PainReform Ltd Announces Receipt Of Extension To Meet The Nasdaq’S Minimum Bid Price Requirement
Brief: PainReform Provides Business Update For The Third Quarter Of 2022